The U.S. pharmaceuticals industry could record double-digit sales growth in 1997, according to third- quarter figures analyzed by IMS America, Plymouth Meeting, PA.
The U.S. pharmaceuticals industry could record double-digit sales growth in 1997, according to third- quarter figures analyzed by IMS America, Plymouth Meeting, PA.
The research firm reported that, year-to-date through September 1997, drug sales totaled more than $69.4 billion. At the same time last year, sales were 12% lower.
According to Gary Friend, a spokesperson for IMS America, the final sales tally for pharmaceutical products in 1997 could easily climb above last year's total. The industry's final sales tally for 1996 was $85.4 billion - 12% greater than the tally the year before.
At press time, IMS America calculated the year-to-date sales through November to be more than $84.6 billion.
Figures were calculated according to data gathered from independent and chain pharmacies, mass merchandisers, proprietary stores, food-store pharmacies, non-federal hospitals, federal facilities, clinics, long-term care facilities and HMOs.
New products and line extensions were responsible for 9% of the prescription drug industry's high-powered growth in the third quarter of 1997, compared with 6.7% in the third quarter of 1996.
"This year, more than one-third of the industry's growth has come from products less than two years old," said Myron Holubiak, general manager of IMS America's consulting and analysis division.
The best-selling drug in the United States is Astra-Merck's Prilosec, according to the firm's product ranking analysis. Its sales reached nearly $1.7 billion in the first three quarters of 1997, a 37% year-to-date increase over the previous year. It outperformed last year's leader, Glaxo Wellcome's Zantac, which lost its patent protection mid-1997.
Other top-selling products included Eli Lilly's Prozac, Roerig's Zoloft, SmithKline Beecham's Paxil, Merck's Zocor and Schering-Plough's Claritin.
Anti-ulcer medicines, such as Prilosec and Zantac, remained the sales leader among therapeutic classes. They accounted for 6.7% of total sales, or $4.7 billion, during the first nine months of 1997.
Other therapeutic classes that demonstrated significant sales growth last year included antipsychotics, up 68%; oral diabetes products, up 45%; prescription cholesterol reducers, up 38%; and oral antihistamines, up 30%.
The industry's sales leaders are Bristol-Myers Squibb and Glaxo Wellcome. Johnson & Johnson, Merck, American Home Products and Pfizer were also among the industry's sales leaders.
By the end of the third quarter, prescription volume totaled nearly 1.9 billion, a 5% increase over the same time period in 1996.
Premarin, manufactured by Wyeth-Ayerst, was the most prescribed medicine with a generous 33.6 million dispensed prescriptions.
Non-injectable codeine and combinations supplanted calcium channel blockers as the most commonly prescribed therapeutic class of drugs.
Among the major pharmaceutical corporations, American Home Products dispensed the most prescriptions - 125.8 million. Bristol-Myers Squibb and Novartis followed closely behind, each registering more than 100 million prescriptions through the third quarter. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.